US Patent

US8722037 — X-ray visible drug delivery device

Formulation · Assigned to Merck Sharp and Dohme BV · Expires 2027-09-28 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.

USPTO Abstract

The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.

Drugs covered by this patent

Nexplanon (ETONOGESTREL)

Patent Metadata

Patent number: US8722037
Jurisdiction: US
Classification: Formulation
Expires: 2027-09-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Merck Sharp and Dohme BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.